Tag:
contract manufacturing
Latest Headlines
Latest Headlines
CMO adds 200 medical device jobs in Ireland
Contract manufacturer Nypro is bolstering its medical device capabilities, planning to launch another factory in Ireland and employ 200 people in the process.
Patheon's Banner buyout adds to losses
Patheon's $225 million buyout last year of Mexico's Banner Pharmacaps gave the contract manufacturer a beachhead in the fast-growing Latin market.
Patheon picks up plant in hot Latin market
It's a done deal. Patheon has concluded its buyout of Banner Pharmacaps, a move that gives it four more manufacturing operations, 1,200 more employees and a foothold in the rapidly growing Latin market.
Device manufacturer Onyx snapped up by Sparton for $43.25M
Onyx, a South Dakota manufacturer of medical devices, will soon be part of Sparton Corporation, as the industrial devicemaker has inked a deal to buy the company for $43.25 million in cash.
Mayne Pharma to pay $120 millon for Metrics
Mayne Pharma, an Australia-based drugmaker, has jumped the Pacific to buy Metrics, a privately owned U.S. niche drug developer and contract manufacturer, in a deal that could reach $120 million.
Baxter inks supply deal for key blood-derived meds
Baxter International ($BAX) aims to beef up capacity for its plasma-derived meds through its new manufacturing services deal with Sanquin Blood Supply Foundation in the Netherlands.
CMO execs reflect on changing manufacturing front
As a Genetic Engineering & Biotechnology News story reveals, they are embracing strategic partnerships and adding capabilities to their arsenal to ensure long-term success.
Nice Insight looks at outsourcing trends from drug developer POV
Nice Insight has released its own study showing what drug developers hope to do with their CRO and CMO partners.
ScinoPharm to build $37M Taiwan plant for cancer injectables
ScinoPharm is investing NT$1.1 billion ($37.6 million) in the construction of a plant in Tainan, Taiwan. The purpose of the plant: to produce injectable cancer drugs, according to the CMO.
FDA pressures on biopharma expected to boost CMOs
Experts cited by Outsourcing-Pharma contribute the shift to a combination of biopharma companies outsourcing more non-core duties and regulatory pressures that lead them to find alternate providers.
